SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

KTA CRYPTO is drawing significant attention as a Layer 1 network building high-speed, compliance-first financial infrastructure, with a recent integration of a fiat anchor from a Stripe company enabling seamless transfers. The community is actively discussing its potential as an undervalued "asymmetric bet" set to become a foundational layer for global financial plumbing. This positioning, coupled with its proven throughput and regulatory readiness, makes it a compelling opportunity amidst the evolving crypto landscape.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as the community celebrates the FDA approval of YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy in adults and children, sparking immense optimism among long-term investors. Many are eagerly discussing the potential for a significant re-rating of the company's valuation and a substantial short squeeze. This milestone, coupled with a multi-billion dollar partnership, has led to widespread belief that the company is now de-risked and poised for considerable growth.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is experiencing significant upward momentum, driven by recent regulatory relief, its ongoing strategic transformation, and strong Q3 earnings reported across the financial sector. This rally has propelled the stock to multi-year highs, sparking community debate about its sustainability amidst indicators of overbought conditions and discussions around notable corporate buybacks.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending as substantial insider buying, coupled with a public offering, conveys management's confidence despite a regulatory complete response letter for one of its lead programs. Community discussion is further energized by encouraging early clinical data for its experimental cancer treatment, BHV-1510, which demonstrated notable response rates and a favorable safety profile. Investors are now closely watching for upcoming readouts from its major depressive disorder and epilepsy programs for additional catalysts.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following its recent FDA approval of Aqvesme, establishing it as the sole approved treatment for anemia in alpha- and beta-thalassemia. While the community is excited about this significant milestone, discussion is also focusing on the immediate stock dip, attributed to the mandated Risk Evaluation and Mitigation Strategy (REMS) program and a delayed commercial availability into early 2026.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending after promising preliminary Phase 3 data for its breast cancer immunotherapy showed an estimated 80% reduction in recurrence rates, driving intense bullish sentiment. The community is actively discussing perceived undervaluation, continued insider buying by the CEO, and the escalating potential for a significant short squeeze, fueled by exceptionally high borrow rates and a tightly held float.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is currently a major talking point following the announcement that Sanofi has agreed to acquire the company for $15.50 per share, a deal valued at approximately $2.2 billion to expand Sanofi's adult immunization offerings. While many investors are celebrating the long-awaited exit and the premium offered, a significant portion of the community expresses strong disappointment, arguing the acquisition price notably undervalues Dynavax's Hepatitis B vaccine and promising shingles pipeline.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, a major milestone for direct-to-device 4G/5G connectivity from low Earth orbit. Despite the positive news, the stock experienced a "sell the news" dip, leading to community debate between short-term profit-takers and long-term investors who highlight future launches and the de-risking of ASTS's technology.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

Opgen (OPGN) is actively discussed for its strategic pivot to an AI-driven fintech platform, CapForce, aimed at Asian markets, backed by significant investment and management changes from AEI Capital. This fundamental business transformation, alongside ongoing efforts to regain Nasdaq listing compliance, is generating strong community enthusiasm, with many anticipating a substantial revaluation once CapForce is fully operational and the stock is relisted.

xCellar is a DeFi protocol powered by the Fawkes Formula, providing untraceable and secure transactions on the blockchain. It's designed to give users complete financial privacy and control over their assets. The Fawkes Formula is our proprietary security protocol that forms the core of xCellar's untraceable transaction system. It utilizes advanced zero-knowledge proofs and cryptographic techniques to ensure complete anonymity.

Xcellar

Xcellar (XCL) is currently trending as its community eagerly anticipates the imminent conclusion of the Sentinel pre-sale and the rollout of major protocol updates, including an enhanced dashboard and rewards system. There's significant buzz around its privacy-focused trading protocol and upcoming token burn events, with many believing it offers substantial growth potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

twitter

$70,000 - $80,000

$80,001 - $90,000

$90,001 - $100,000

Other (Comment Below)

Bitcoin has seen massive volatility this quarter as ETFs, macro conditions, and crypto adoption continue to shape price action. As 2025 comes to a close, where do you think Bitcoin ($BTC) will finish on December 31, 2025 (EST)?

Where Will Bitcoin Close on Dec 31, 2025?

CC0COMPANY
CC0 COMPANY

Chart

News

Sentiment

Info

Historical Prices

Poll

Latest CC0COMPANY News

CC0COMPANYCC0 COMPANY